The effect of a methylxanthine vasodilator: pentoxifylline on the treatment of diabetic nephropathy—a meta-analysis
Authors:
- 21 November 2023
- journal article
- review article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (5) , 1-15
Abstract
This meta-analysis aimed to comprehensively evaluate the efficacy and safety of pentoxifylline (PTF) in the treatment of diabetic nephropathy (DN) and to offer fresh perspectives and evidence-based references for this condition. Meta-analysis. Relevant randomized controlled trials (RCTs) were searched from PubMed, Embase, Cochrane Library, China Knowledge Network (CNKI), Wanfang, and China Biomedical Literature Database. All trials were screened for compliance with the inclusion and exclusion criteria, and relevant data were extracted after quality evaluation. Eighteen studies with a total of 1280 patients were finally included. Compared to the control group, high sensitivity C-reactive protein (hsCRP) was improved (MD = − 0.23. 95% CI = [− 0.41, − 0.05], P = 0.01); urinary albumin excretion (UAE) rate was reduced (MD = − 16.50, 95% CI = [− 18.87, − 14.13], PP = 0.009); fasting plasma glucose (FPG) was decreased (MD = − 5.66, 95% CI = [− 9.79, − 1.53], P = 0.007); and the improvement of glomerular filtration rate (eGFR) from baseline was increased (MD = 4.38, 95% CI = [3.28, 5.48], P<0.00001) in the treatment group. No significant difference was observed between the two groups concerning systolic blood pressure, diastolic blood pressure, total cholesterol, and triglycerides. And in terms of safety, the use of PTF was relatively safe with some self-limiting adverse events. FPG was decreased by PTF more effectively, but there was no effect of PTF on glycated hemoglobin (HbA1c). PTF could improve hsCRP, decrease UAE and Scr, and raise eGFR in the treatment of DN.Keywords
This publication has 36 references indexed in Scilit:
- Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysisInternational Urology and Nephrology, 2015
- Effect of Pentoxifylline on Renal Function and Urinary Albumin Excretion in Patients with Diabetic Kidney DiseaseJournal of the American Society of Nephrology, 2015
- Pentoxifylline for diabetic kidney diseaseCochrane Database of Systematic Reviews, 2012
- Captopril and Combination Therapy of Captopril and Pentoxifylline in Reducing Proteinuria in Diabetic NephropathyRenal Failure, 2010
- The Effect of Pentoxifylline on Proteinuria in Diabetic Kidney Disease: A Meta-analysisAmerican Journal of Kidney Diseases, 2008
- Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria – A double-blind, placebo-controlled randomized trialClinical Nephrology, 2006
- Additive Antiproteinuric Effect of Pentoxifylline in Patients with Type 2 Diabetes under Angiotensin II Receptor BlockadeJournal of the American Society of Nephrology, 2005
- Pentoxifylline Ameliorates Renal Tumor Necrosis Factor Expression, Sodium Retention, and Renal Hypertrophy in Diabetic RatsAmerican Journal of Nephrology, 2004
- l-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast culturesNitric Oxide, 2003
- Effects of pentoxifylline administration on urinary N-acetyl-β-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized studyAmerican Journal of Kidney Diseases, 2003